In this research, we focused on the positive compound EGCG, which is a new inhibitor of E3 ligase targeting the N-terminal RING domain to potentially prevent and treat melanoma, lung cancer, and other tumors by targeting TRAF6. This evidence concerns the gene TRAF6 and lung carcinoma.